PFE

New York-based Pfizer Inc. (PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. Valued at a market cap of $139.5 billion, the company operates in three segments: Biopharma, PC1, and Pfizer Ignite. PFE is expected to release its Q2 2026 earnings on Tuesday, Aug. 4, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $0.68 on a diluted basis, down 12.8% from $0.78 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in all of its last four quarters. Dear Google Stock Fans, Mark Your Calendars for July 13 Oracle Stock Crashes to a 52-Week Low. Here’s Why It Might Be Time to Buy. Costco vs. Walmart: 1 Dividend-Paying Retail Giant Stands Above the Other Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For fiscal 2026, analysts project the company’s EPS to be $2.96, down 8.1% from $3.22 in fiscal 2025. Moreover, its EPS is expected to fall by roughly 3.4% year over year (YoY) to $2.86 in fiscal 2027. PFE stock has declined 4.4% over the past 52 weeks, lagging behind the S&P 500 Index’s ($SPX) 20.1% rise and the State Street Healthcare Select Sector SPDR ETF’s (XLV) 19.4% rise during the same time frame. On May 5, PFE stock rose marginally following the release of its Q1 2026 earnings. The company’s revenue for the quarter amounted to $14.5 billion and surpassed the Street’s forecasts. Moreover, its adjusted EPS came in at $0.75, also coming in on top of Wall Street’s estimates. Pfizer expects full-year earnings in the range of $2.80 to $3 per share, with revenue in the range of $59.5 billion to $62.5 billion. Analysts are moderately optimistic about PFE, with the stock having a “Moderate Buy” rating overall. Among the 28 analysts covering the stock, eight recommend a “Strong Buy,” one recommends a “Moderate Buy,” 17 recommend a “Hold,” and two recommend a “Strong Sell.” PFE’s average analyst price target is $28.80, indicating an 18.4% upside from current levels. On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally...

Pfizer PFE is one of the world’s leading oncology drugmakers, with a strong presence across breast, genitourinary, thoracic, gastrointestinal and hematologic cancers. The company has built a broad portfolio of marketed cancer therapies and maintains a deep oncology pipeline spanning multiple treatment modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. Oncology sales comprise around 27% of its total revenues. Its oncology revenues grew 7% to $3.8 billion in the first quarter of 2026. Investors will be keen to know how its oncology segment performed in the second quarter when the company announces results on Aug. 4. Pfizer’s oncology sales in the second quarter are expected to have been driven by higher sales of key drugs like Padcev, Lorbrena and the Braftovi-Mektovi combination, which should make up for declining sales of drugs like Ibrance and Adcetris. Sales of the new drug, Elrexfio, are also likely to have risen in the quarter. The Zacks Consensus Estimate for Padcev is $661 million, while that for Ibrance is $1.05 billion. Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Its oncology biosimilars are expected to have made a significant contribution to sales growth in the second quarter of 2026, similar to the past few quarters. Pfizer is also likely to provide updates on its key oncology candidates on the second-quarter conference call. Several oncology candidates have entered late-stage development, such as atirmociclib and sigvotatug vedotin. A regulatory application seeking approval of sasanlimab is also under review in the EU. Last year, Pfizer entered into a global ex-China in-licensing agreement with China's 3SBio for exclusive rights to PF-08634404, a dual PD-1 and VEGF inhibitor, which it plans to establish as a potential backbone therapy across multiple tumor types. Pfizer plans to start four pivotal studies for PF-08634404 in 2026. An update on PF-08634404 is expected on the second-quarter conference call. Pfizer is one of the largest drugmakers of cancer medicines. Other large players in the oncology space are AstraZeneca AZN, Merck MRK, J&J JNJ and Bristol-Myers. For J&J, the Oncology segment comprises around 29% of total revenues and 45% of its Innovative Medicine segment sales. Its oncology sales rose 17.8% on an operational basis in the first...

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growt

Pfizer's (PFE) second-quarter revenue is expected to match Wall Street's estimates, while its earnin

Nike's (NKE) fiscal fourth-quarter revenue slipped year-over-year, while the sportswear company's ea

Board of Directors approves quarterly cash dividend of $0.43 per share NEW YORK, June 24, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company’s common stock, payable September 1, 2026, to holders of the Common Stock of record at the close of business on July 24, 2026. Pfizer is committed to maintaining, and over the longer term, growing the dividend, as part of its capital allocation strategy. The third-quarter 2026 cash dividend will be the 351st consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For over 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. Disclosure Notice: The information contained in this release is as of June 24, 2026. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments. This release contains forward-looking information about, among other things, Pfizer’s commitment to maintaining, and over the longer term, growing the dividend, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inhere...

Pfizer, however, highlighted encouraging trends in a key prespecified subgroup. Sigvotatug vedotin is part of Pfizer’s efforts to deliver eight potential cancer drug breakthroughs by 2030. Pfizer acquired Seagen in 2023 for a total enterprise value of approximately $43 billion to expand its cancer pipeline. Pfizer (PFE) shares slipped nearly 2% in after-hours trading on Monday after the company reported mixed topline results from a pivotal late-stage trial of its investigational antibody-drug conjugate sigvotatug vedotin in previously treated metastatic non-squamous non-small cell lung cancer. The stock closed the regular session at $25.08 before falling to around $24.71 after hours, as investors digested the news that the drug failed to meet its primary endpoint of overall survival in the overall study population. See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox Pfizer announced results from the SigVie-002 study, which evaluated sigvotatug vedotin versus docetaxel in 703 patients with locally advanced, unresectable or metastatic non-squamous NSCLC who had received one or more prior lines of therapy. In the overall population, sigvotatug vedotin did not demonstrate a statistically significant improvement in overall survival compared with docetaxel. The primary endpoint was therefore not met. However, the company highlighted encouraging trends in a key prespecified subgroup: patients who had received only one prior line of systemic therapy, representing approximately two-thirds of the enrolled population. In this second-line group, sigvotatug vedotin showed stronger signals favoring both overall survival and progression-free survival over docetaxel. Descriptive secondary endpoints, including progression-free survival, confirmed objective response rate, and duration of response, also supported positive trends in the second-line setting, the company said. The safety profile of sigvotatug vedotin was described as manageable and consistent with earlier clinical studies. “Patients with previously treated advanced NSCLC are a historically difficult-to-treat population, and there is clearly more work to be done to improve the outcomes for this population,” Jeff Legos, Chief Oncology Officer, said. “Although the overall study results did not demonstrate superiority over docetaxel, it is...

NEW YORK, June 22, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who had received one or more lines of prior therapy. In the overall population, sigvotatug vedotin did not show a statistically significant improvement in the primary endpoint of overall survival (OS) compared to docetaxel. The safety profile of sigvotatug vedotin was manageable and consistent with prior studies. Encouragingly, in patients who received only one prior line of systemic therapy, which represents two-thirds of the study population, a stronger trend was observed for OS and progression-free survival (PFS) for sigvotatug vedotin over docetaxel. In the exploratory analysis, no clear IB6 expression-response relationship was observed. Detailed results from SigVie-002 will be submitted for presentation at a future medical congress. "Patients with previously treated advanced NSCLC are a historically difficult-to-treat population, and there is clearly more work to be done to improve the outcomes for this population," said Jeff Legos, Chief Oncology Officer, Pfizer. "Although the overall study results did not demonstrate superiority over docetaxel, it is encouraging that second-line patients treated with sigvotatug vedotin achieved strong efficacy outcomes compared to an established standard of care, alongside a manageable safety profile. This observed clinical benefit, along with our Phase 1 combination data in the first-line setting, reinforces our confidence in the potential of the sigvotatug vedotin program, including an ongoing Phase 3 trial in combination with pembrolizumab in first-line advanced NSCLC." "It is important not to underestimate the activity of docetaxel as a comparator in this setting. Patients enrolled in this trial were heavily pre-treated, with most having previously received both platinum-based chemotherapy and immunotherapy, yet docetaxel continues to provide meaningful clinical benefit. Although the study did not meet its overall survival endpoint, in second-line patients the data suggest a clinically meaning...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b pharmaceutical group is positioned, with value metrics and recent returns drawing closer scrutiny. See our latest analysis for Pfizer. Pfizer’s recent share price has softened, with the stock down 6.53% on a 90 day share price return basis, while the 1 year total shareholder return of 12.52% reflects a different experience for investors over a longer period. If Pfizer’s recent moves have you reassessing the sector, it could be a good moment to broaden your watchlist with 40 healthcare AI stocks With Pfizer shares softening over the past quarter but showing a 12.52% total return over 1 year and an indicated intrinsic discount of 59.79%, investors are left asking: is this stock undervalued, or is future growth already priced in? Based on the most followed narrative, Pfizer’s fair value of $28.00 sits modestly above the last close at $25.21, which frames the current discount as relatively measured rather than extreme. Read the complete narrative. Want to unpack why this narrative still sees upside for Pfizer even with declining revenue and earnings forecasts? The core assumptions turn on how quickly COVID revenue fades, how much the current pipeline fills the patent cliff gap, and what margin profile the business can sustain once one off items clear. The full narrative spells out those building blocks in detail, including how they link to that $28.00 fair value tag. Result: Fair Value of $28.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this Pfizer narrative could be knocked off course if revenue and net income, which both declined on an annual basis, weaken further or if key products disappoint. Find out about the key risks to this Pfizer narrative. If the differing views in this Pfizer story leave you uncertain, take that as your prompt to move quickly, review the data, and weigh both the 1 key reward and 4 important warning signs for yourself with 1 key reward and 4 important warning signs If Pfizer has sharpened your focus, do not stop there. Use the screener to spot fresh opportunities now, before other investors start paying closer attention. Spot potential bargains early by sca...

Pfizer (PFE) shares fell 2.6% in Thursday trading after the company reaffirmed its fiscal 2026 guida

It has been about a month since the last earnings report for Pfizer (PFE). Shares have lost about 4.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Pfizer due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Pfizer Inc. before we dive into how investors and analysts have reacted as of late. Pfizer reported first-quarter 2026 adjusted earnings per share of 75 cents, which beat the Zacks Consensus Estimate of 71 cents per share. Earnings declined 18% year over.Revenues came in at $14.45 billion, up 5% from the year-ago quarter on a reported basis and 2% on an operational basis. Total revenues beat the Zacks Consensus Estimate of $13.82 billion. Higher revenues for Padcev, Eliquis, oncology biosimilars and others made up for the decline in sales of COVID products, Comirnaty and Paxlovid.Sales of non-COVID products rose 7% in the quarter on an operational basis. Pfizer’s newly launched and acquired products delivered revenues of $3.1 billion in the first quarter, rising 22% operationally.International revenues declined 1% on an operational basis to $5.72 billion. U.S. revenues rose 4% to $8.73 billion. Adjusted selling, informational and administrative (SI&A) expenses declined 5% (operationally) in the quarter to $2.92 billion due to ongoing productivity improvements, which led to lower marketing and promotional spend for various products. Adjusted R&D expenses rose 11% to $2.43 billion due to higher spending on oncology and obesity pipeline. Pfizer reports its revenues under three broad sub-segments of its Biopharma operating segment — Primary Care, Specialty Care and Oncology. In first-quarter 2026, Pfizer created a new Hospital and Biosimilars Division within its Biopharma segment, moving certain off-patent brands, generic sterile injectables and biosimilars out of Specialty Care and Oncology. Sales of the Primary Care segment declined 6% operationally to $5.54 billion. The Specialty Care unit recorded sales of $2.94 billion, up 8%. Sales of Oncology rose 7% to $3.83 billion. Sales in the Hospital and Biosimilars segment rose 10% to $1.85 billion in the first quarter. In Primary Care, alliance revenues and direct sales from Eliquis rose 8% to $2.17 billion as higher demand...

Pfizer Inc. (NYSE:PFE) ranks among the best retirement stocks to buy now. On May 5, BofA Securities boosted its price objective for Pfizer Inc. (NYSE:PFE) to $27 from $26, retaining a Neutral rating on the company shares. Following Pfizer’s first-quarter performance, the firm raised its fiscal 2026 revenue and earnings per share forecasts. The pharmaceutical giant reported adjusted earnings per share of $0.75, 4.17% more than the consensus forecast of $0.72, while revenue of $14.5 billion exceeded expectations of $13.84 billion by 4.77%. Ignoring COVID-related products, Pfizer’s core business increased by 7% operationally. BofA remarked that Pfizer’s long-term revenue CAGR target for 2028-2033 is significantly higher than the consensus. BofA sees meeting this aim as questionable and potentially skewed toward obesity therapies, where the market landscape is very competitive. Additionally, Pfizer Inc. (NYSE:PFE) revealed details regarding a 35-valent pneumococcal conjugate vaccine that is ready for Phase 1. According to BofA, the absence of supporting data and the capacity to resolve protein carrier suppression, a major concern regarding ultra-high valent pneumococcal vaccines, still need to be determined. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. The company offers medicines and vaccines in various therapeutic areas. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years Disclosure: None. Follow Insider Monkey on Google News.